Does the benefit from statin therapy extend beyond 5 years?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Large randomized trials demonstrate statins rapidly reduce LDL cholesterol, vascular morbidity, and mortality.
• Limited data exist on the long-term efficacy and safety of statin treatment.
• Post-trial follow-up is crucial for assessing sustained benefits and potential hazards.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of statin therapy beyond the initial trial period.
• To assess the cumulative benefits and cost-effectiveness of sustained LDL cholesterol reduction.
• To investigate potential long-term adverse effects, including cancer incidence and non-vascular mortality.

Main Methods:

• Long-term follow-up of participants from large randomized statin trials, including the Heart Protection Study.
• Analysis of vascular morbidity and mortality rates during extended post-trial periods.
• Assessment of cancer incidence and non-vascular mortality during extended follow-up.

Main Results:

• Post-trial follow-up confirmed substantial absolute benefits and cost-effectiveness of statin therapy, often underestimated by in-trial analyses.
• Extended follow-up of the Heart Protection Study revealed no increased incidence of cancer.
• No adverse effects on non-vascular mortality were observed during the extended follow-up period.

Conclusions:

• Sustained statin therapy provides significant long-term vascular benefits.
• The overall benefits and cost-effectiveness of statins are greater than previously estimated.
• Long-term statin continuation is supported by evidence of safety, including no increased cancer risk or non-vascular mortality.